MX2023000693A - Inhibidor de egfr. - Google Patents
Inhibidor de egfr.Info
- Publication number
- MX2023000693A MX2023000693A MX2023000693A MX2023000693A MX2023000693A MX 2023000693 A MX2023000693 A MX 2023000693A MX 2023000693 A MX2023000693 A MX 2023000693A MX 2023000693 A MX2023000693 A MX 2023000693A MX 2023000693 A MX2023000693 A MX 2023000693A
- Authority
- MX
- Mexico
- Prior art keywords
- egfr
- egfr inhibitor
- salt
- formula
- active ingredient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020121525 | 2020-07-15 | ||
| PCT/JP2021/026461 WO2022014639A1 (ja) | 2020-07-15 | 2021-07-14 | Ｅｇｆｒ阻害剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000693A true MX2023000693A (es) | 2023-02-13 |
Family
ID=79554696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000693A MX2023000693A (es) | 2020-07-15 | 2021-07-14 | Inhibidor de egfr. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230285397A1 (enExample) |
| EP (1) | EP4197538A4 (enExample) |
| JP (1) | JP7495983B2 (enExample) |
| KR (1) | KR102873219B1 (enExample) |
| CN (1) | CN116368136B (enExample) |
| AU (1) | AU2021309779B2 (enExample) |
| BR (1) | BR112023000770A2 (enExample) |
| CA (1) | CA3189460A1 (enExample) |
| MX (1) | MX2023000693A (enExample) |
| PH (1) | PH12023550119A1 (enExample) |
| TW (1) | TW202216152A (enExample) |
| WO (1) | WO2022014639A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022014638A1 (ja) * | 2020-07-15 | 2022-01-20 | 大鵬薬品工業株式会社 | ピリミジン化合物の結晶 |
| AU2021308045B2 (en) * | 2020-07-15 | 2024-06-20 | Taiho Pharmaceutical Co., Ltd. | Pyrimidine compound-containing combination to be used in tumor treatment |
| EP4351737A4 (en) * | 2021-05-24 | 2025-05-14 | Taiho Pharmaceutical Co., Ltd. | Treatment methods for subjects with cancer having an aberration in egfr and/or her2 |
| KR20250164828A (ko) | 2023-03-30 | 2025-11-25 | 레볼루션 메디슨즈, 인크. | Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8426428B2 (en) * | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
| US9034885B2 (en) * | 2012-01-13 | 2015-05-19 | Acea Biosciences Inc. | EGFR modulators and uses thereof |
| TW201336847A (zh) * | 2012-02-07 | 2013-09-16 | Taiho Pharmaceutical Co Ltd | 喹啉基吡咯并嘧啶化合物或其鹽 |
| DK3345907T3 (da) * | 2015-09-01 | 2020-06-22 | Taiho Pharmaceutical Co Ltd | Pyrazolo[3,4-d]pyrimidinforbindelser eller salte deraf |
| MD3269370T2 (ro) * | 2016-02-23 | 2020-05-31 | Taiho Pharmaceutical Co Ltd | Compus pirimidinic condensat nou sau sare a acestuia |
| MA54702A (fr) * | 2019-01-11 | 2021-11-17 | Taiho Pharmaceutical Co Ltd | Composé pyrimidine ou sel correspondant |
-
2021
- 2021-07-14 CA CA3189460A patent/CA3189460A1/en active Pending
- 2021-07-14 TW TW110125853A patent/TW202216152A/zh unknown
- 2021-07-14 PH PH1/2023/550119A patent/PH12023550119A1/en unknown
- 2021-07-14 WO PCT/JP2021/026461 patent/WO2022014639A1/ja not_active Ceased
- 2021-07-14 EP EP21842292.1A patent/EP4197538A4/en active Pending
- 2021-07-14 CN CN202180061165.8A patent/CN116368136B/zh active Active
- 2021-07-14 MX MX2023000693A patent/MX2023000693A/es unknown
- 2021-07-14 BR BR112023000770A patent/BR112023000770A2/pt unknown
- 2021-07-14 US US18/016,103 patent/US20230285397A1/en active Pending
- 2021-07-14 KR KR1020237001973A patent/KR102873219B1/ko active Active
- 2021-07-14 AU AU2021309779A patent/AU2021309779B2/en active Active
- 2021-07-14 JP JP2022536419A patent/JP7495983B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023000770A2 (pt) | 2023-02-07 |
| KR102873219B1 (ko) | 2025-10-17 |
| TW202216152A (zh) | 2022-05-01 |
| KR20230026451A (ko) | 2023-02-24 |
| PH12023550119A1 (en) | 2024-06-24 |
| CN116368136B (zh) | 2025-09-05 |
| AU2021309779B2 (en) | 2024-06-27 |
| JPWO2022014639A1 (enExample) | 2022-01-20 |
| JP7495983B2 (ja) | 2024-06-05 |
| EP4197538A4 (en) | 2024-08-07 |
| CN116368136A (zh) | 2023-06-30 |
| AU2021309779A1 (en) | 2023-02-23 |
| US20230285397A1 (en) | 2023-09-14 |
| CA3189460A1 (en) | 2022-01-20 |
| WO2022014639A1 (ja) | 2022-01-20 |
| EP4197538A1 (en) | 2023-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023000693A (es) | Inhibidor de egfr. | |
| CO2018012894A2 (es) | Derivados de pirazol como inhibidores de calicreína plasmática | |
| CO2021006075A2 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp | |
| MX2018002520A (es) | Compuesto novedoso de pirazolo[3,4-d] pirimidina o sal del mismo. | |
| DOP2021000088A (es) | Compuestos de azalactam como inhibidores de hpk1 | |
| UY37461A (es) | 1,2,4 – triazolonas 2,4,5 trisustituida | |
| UY37201A (es) | Nuevos derivados de pirazolopirimidina | |
| CL2020001752A1 (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa. | |
| PE20151542A1 (es) | Compuestos de tetrahidropirrolotiazina | |
| MX2021014049A (es) | Compuestos espiro triciclicos. | |
| CL2019001495A1 (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih. | |
| PE20151892A1 (es) | Compuestos tetraciclicos sustituidos con heterociclo y metodos de uso de los mismos para el tratamiento de enfermedades viricas | |
| MX2018003311A (es) | Ácido nucleico artificial puenteado a guanidina, entrelazado, método para la producción del mismo, y compuesto intermediario. | |
| MX2018009861A (es) | Compuesto novedoso de tiofeno 2,3,5-sustituido como inhibidor de la proteina cinasa. | |
| MX2022001004A (es) | Inhibidores de enzimas. | |
| MX2024009943A (es) | Inhibidores de arn helicasa dhx9 y usos de los mismos | |
| CO2022015630A2 (es) | Pirrolopirimidinaminas como inhibidores del sistema del complemento | |
| CO2017007076A2 (es) | Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo | |
| MX2019013291A (es) | Compuestos y metodos para tratar infecciones bacterianas. | |
| ECSP22068087A (es) | Métodos de control o prevención del mal de Panamá en plantas de plátano | |
| CR10524A (es) | Compuesto triciclico y uso farmaceutico del mismo | |
| MX2024001270A (es) | Compuestos heterociclicos para el tratamiento de la epilepsia. | |
| CL2019002025A1 (es) | Derivados de pirrolotriazina como inhibidor de cinasas. | |
| MX2019002314A (es) | Compuesto de 1-acetil-fenil urea, y uso del mismo. | |
| MX2017009863A (es) | Agente preventivo y/o terapeutico de enfermedad inmune. |